Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTARTERIAL: Intra-arterial Lutathera in GEP-NET Liver Metastases
NCT04837885Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Standardized uptake value (SUVmax) on liver metastases at Day 3. Started Sep 2021; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04837885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837885.